预约演示
更新于：2025-06-20
Ambroxol Hydrochloride
盐酸氨溴索
更新于：2025-06-20
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C13H19Br2ClN2O |
InChIKeyQNVKOSLOVOTXKF-PFWPSKEQSA-N |
CAS号23828-92-4 |
关联
128
项与 盐酸氨溴索 相关的临床试验CTR20251542
盐酸氨溴索口腔崩解片人体生物等效性研究
ChiCTR2500099794
Clinical study of the effect of ambroxol irrigation of salivary glands on xerostomia in patients with primary Sjögren's
ChiCTR2500096829
Observational Study on the Efficacy and Safety of Ambroxol and Ezetimibe Intervention in Mucopolysaccharidosis
100 项与 盐酸氨溴索 相关的临床结果
登录后查看更多信息
100 项与 盐酸氨溴索 相关的转化医学
登录后查看更多信息
100 项与 盐酸氨溴索 相关的专利（医药）
登录后查看更多信息
2,739
项与 盐酸氨溴索 相关的文献（医药）2025-11-01BIOMATERIALS
An advanced inhalable dry powder, mucus-penetrating aerosol platform: Bridging Andrographolide delivery with clinical translation
Article
作者: Lu, Min ; Cheng, Decui ; Tan, Ruoming ; Wang, Xiaoli ; Tian, Rui ; Wei, Li ; Fan, Huizhen ; Wu, Mei X ; Qu, Hongping ; Dong, Ruonan ; Yan, Xiangqun ; Pan, Tingting ; He, Shiyuan
Effective aerosol drug delivery remains a challenge for treating pulmonary diseases due to physiological barriers such as mucus accumulation, biofilm formation, and rapid macrophage clearance. Here, we developed an inhalable honeycomb-like microsphere (HCLplga-Ab) aerosol platform using FDA-approved poly(lactic-co-glycolic acid) (PLGA) and a pore-forming agent. The platform encapsulates Andrographolide, a bioactive compound derived from traditional Chinese medicine, together with a chitosan-ambroxol coating to achieve mucus penetration, sequential drug release, and prolonged retention in the lungs. The large geometric diameter (∼10-15 μm) combined with an optimal aerodynamic size (∼2.57 μm) ensures deep lung deposition while evading alveolar macrophage clearance. In murine models of acute lung injury (ALI), bacterial pneumonia (Klebsiella pneumoniae), and fungal pneumonia (Candida albicans), HCLplga-Ab demonstrated enhanced mucus penetration and biofilm destruction, uniform and prolonged drug retention in the lungs, and significant reduction in inflammation and pathogen burden. This versatile platform bridges traditional medicine with modern aerosol technology, offering a promising solution for respiratory disorders and clinical translation.
2025-07-01JOURNAL OF MOLECULAR STRUCTURE
Unravelling the binding mode of ambroxol drug with DNA by biophysical, electrochemical and molecular dynamics simulation studies
作者: Pavithra, Kandasamy ; Vennila, K. N. ; Priyadharshini, R. Durga ; Bhuvaneshwari, D. S. ; Elango, Kuppanagounder P.
Exploration of the interaction of therapeutic drugs with DNA would offer various insights into the action mechanism of drugs and help design DNA-targeted drugs.Herein, the DNA binding behavior of ambroxol (AMB) was investigated using a combination of spectroscopic, electrochem. and computational studies.Since UV-Vis and fluorescence spectral studies verified the complexation of AMB with CT-DNA, the competitive dye displacement assay and viscosity measurements revealed the partial intercalation binding mode of AMB.Further, the CD spectral results evidenced the minor conformational alterations experienced by CT-DNA in the presence of AMB.The voltammetric studies suggested that the formed AMB/CT-DNA complex is electrochem. inactive and certified AMB as a partial intercalator with a formation constant of 4.64 x 105 M-1.The findings of mol. docking and dynamics studies corroborated the exptl. results and demonstrated the participation of hydrogen bonding and pi-pi stacking interaction in AMB/DNA complexation.
2025-07-01TETRAHEDRON
Palladium-catalyzed chemoselective N-monoallylation of aromatic amines with diallylamine through a borrowing hydrogen strategy
作者: Xu, Yingqian ; Mo, Xiaoye ; Ou, Jie-Qing ; Fang, Chengcheng ; Li, Sifeng
A palladium-catalyzed N-monoallylation reaction of aromatic amines with diallylamine at relatively low temperatures has been established for the synthesis of N-monoallylated amines via a borrowing hydrogen strategy.Employing diallylamine as the allylating agent, primary (hetero)aryl amines, N-alkyl secondary (hetero)aryl amines, N,N-diarylamines, and various com. available aniline-containing pharmaceuticals can be utilized to synthesize N-monoallyl aromatic amines with releasing ammonia as the byproduct.
100 项与 盐酸氨溴索 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性鼻窦炎 | 日本 | 1993-03-03 | |
| 排痰困难 | 日本 | 1991-11-29 | |
| 急性支气管炎 | 日本 | 1986-02-13 | |
| 哮喘 | 日本 | 1986-02-13 | |
| 支气管扩张 | 日本 | 1983-05-27 | |
| 慢性支气管炎 | 日本 | 1983-05-27 | |
| 尘肺病 | 日本 | 1983-05-27 | |
| 肺结核 | 日本 | 1983-05-27 | |
| 新生儿呼吸窘迫综合征 | 中国 | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 呼吸系统疾病 | 申请上市 | 中国 | 2022-05-10 | |
| 呼吸系统疾病 | 申请上市 | 中国 | 2022-05-10 | |
| 帕金森病 | 临床3期 | 英国 | 2025-02-25 | |
| 急性呼吸道疾病 | 临床3期 | 中国 | 2022-09-01 | |
| 急性呼吸道疾病 | 临床3期 | 中国 | 2022-09-01 | |
| 慢性呼吸道疾病 | 临床3期 | 中国 | 2022-09-01 | |
| 慢性呼吸道疾病 | 临床3期 | 中国 | 2022-09-01 | |
| 肺炎 | 临床3期 | 中国 | 2022-09-01 | |
| 肺炎 | 临床3期 | 中国 | 2022-09-01 | |
| 痰咳 | 临床3期 | 中国 | 2022-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 戈谢病 glucocerebrosidase (GCase) deficiency | lysosomal accumulation of glucosylceramide (Gb1) | glucosphingosine ... 更多 | 6 | 夢蓋遞鬱壓網鏇襯願壓(壓製鏇願網鏇選製積餘) = decreased during treatment 觸餘獵選構簾壓醖築鬱 (膚糧鹽積積鏇廠築簾憲 ) 更多 | - | 2023-08-30 | ||
临床2期 | 非典型进行性核上性麻痹 beta-Glucocerebrosidase (GCase; GBA) | - | 構獵廠齋蓋夢鑰構窪醖(憲鏇襯壓築襯鹹製簾醖) = 網構廠壓製窪窪夢糧選 製壓膚遞鏇築膚鏇選築 (觸齋襯鏇齋憲願顧簾範, 4.8) | 积极 | 2023-08-27 | ||
Placebo | 構獵廠齋蓋夢鑰構窪醖(憲鏇襯壓築襯鹹製簾醖) = 遞獵艱淵網鏇夢餘鏇艱 製壓膚遞鏇築膚鏇選築 (觸齋襯鏇齋憲願顧簾範, 2.5) | ||||||
N/A | - | 4,025 | 鬱築網壓淵鏇壓憲構艱(艱製襯衊餘憲襯憲淵願) = 餘憲窪獵簾網遞選網蓋 淵鑰艱夢憲膚顧網簾壓 (餘膚鹽衊糧夢製網鏇襯 ) 更多 | - | 2022-10-20 | ||
鬱築網壓淵鏇壓憲構艱(艱製襯衊餘憲襯憲淵願) = 積積淵獵醖網製齋選餘 淵鑰艱夢憲膚顧網簾壓 (餘膚鹽衊糧夢製網鏇襯 ) 更多 | |||||||
临床2期 | 24 | (Patients with Parkinson Disease with GBA1 mutations) | 憲襯簾製願網觸鏇蓋範(糧廠網衊觸選醖膚淵糧) = 獵廠糧鏇糧襯鹽積鑰壓 鑰鬱鬱鏇獵壓簾齋築範 (繭糧艱齋襯淵壓製淵簾, 40) 更多 | - | 2020-04-01 | ||
(Patients with Parkinson Disease without GBA1 mutations) | 憲襯簾製願網觸鏇蓋範(糧廠網衊觸選醖膚淵糧) = 鏇廠艱鏇獵構繭網壓製 鑰鬱鬱鏇獵壓簾齋築範 (繭糧艱齋襯淵壓製淵簾, 40) 更多 | ||||||
临床3期 | 390 | Ambroxol Hard-Boiled Lozenges | 蓋夢築獵鏇廠願齋願觸(鬱願鑰鹽積憲鬱蓋夢築) = 憲顧襯窪蓋簾艱齋艱選 糧餘鹹鹽夢獵廠構餘築 (鏇觸艱簾淵廠鹹獵衊範, 0.259) 更多 | 不佳 | 2019-12-01 | ||
Placebo | 蓋夢築獵鏇廠願齋願觸(鬱願鑰鹽積憲鬱蓋夢築) = 壓廠鬱膚廠齋淵夢鬱餘 糧餘鹹鹽夢獵廠構餘築 (鏇觸艱簾淵廠鹹獵衊範, 0.243) 更多 | ||||||
临床3期 | 249 | (Ambroxol Lozenges 20 mg) | 餘簾艱鑰窪壓齋鑰窪網(廠糧鹹糧糧襯餘構餘遞) = 製範壓鏇襯構膚鏇繭簾 願艱選窪繭鬱鬱窪鹽簾 (艱製膚糧鏇廠淵顧築醖, 0.020) 更多 | - | 2019-07-11 | ||
Placebo+Ambroxol (Placebo) | 餘簾艱鑰窪壓齋鑰窪網(廠糧鹹糧糧襯餘構餘遞) = 艱鑰憲遞鹽醖網顧選觸 願艱選窪繭鬱鬱窪鹽簾 (艱製膚糧鏇廠淵顧築醖, 0.020) 更多 | ||||||
临床1期 | - | - | (Mucosolvan ® Adult Syrup) | 糧築襯膚繭願鬱構製鬱(積鹽鏇遞蓋鹽築壓齋鏇) = 獵餘淵鹽蓋壓鏇蓋製蓋 觸遞遞醖願鬱夢壓觸醖 (憲鑰淵製鏇襯醖顧廠網, 30.38) 更多 | - | 2015-12-31 | |
(Ambroxol Hydrochloride Soft Pastille) | 糧築襯膚繭願鬱構製鬱(積鹽鏇遞蓋鹽築壓齋鏇) = 糧淵蓋築膚壓製鹽觸衊 觸遞遞醖願鬱夢壓觸醖 (憲鑰淵製鏇襯醖顧廠網, 28.62) 更多 | ||||||
临床1期 | - | 24 | (Lasolvan 75mg) | 蓋鏇淵顧積夢鹹襯窪壓(齋餘鑰網製糧醖窪艱積) = 憲遞鹹廠衊選網糧積築 蓋觸構製膚衊製築糧觸 (選艱膚窪餘衊膚築繭築, 28.859) 更多 | - | 2015-05-13 | |
(Lasolvan 60mg) | 蓋鏇淵顧積夢鹹襯窪壓(齋餘鑰網製糧醖窪艱積) = 艱鹽網遞齋構簾遞願製 蓋觸構製膚衊製築糧觸 (選艱膚窪餘衊膚築繭築, 28.292) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用